What You Need to Know About Melanoma and Other Skin Cancers - Services, U. S. Department of Health and; Institute, National Cancer
20,99 €
inkl. MwSt.

Versandfertig in über 4 Wochen
  • Broschiertes Buch

This National Cancer Institute (NCI) booklet is for people diagnosed with the most common types of skin cancer:* ¿ Melanoma ¿ Basal cell skin cancer ¿ Squamous cell skin cancer Skin cancer is the most common type of cancer in the United States. Each year, more than 68,000 Americans are diagnosed with melanoma, and another 48,000 are diagnosed with an early form of the disease that involves only the top layer of skin. Also, more than 2 million people are treated for basal cell or squamous cell skin cancer each year. Basal cell skin cancer is several times more common than squamous cell skin…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
This National Cancer Institute (NCI) booklet is for people diagnosed with the most common types of skin cancer:* ¿ Melanoma ¿ Basal cell skin cancer ¿ Squamous cell skin cancer Skin cancer is the most common type of cancer in the United States. Each year, more than 68,000 Americans are diagnosed with melanoma, and another 48,000 are diagnosed with an early form of the disease that involves only the top layer of skin. Also, more than 2 million people are treated for basal cell or squamous cell skin cancer each year. Basal cell skin cancer is several times more common than squamous cell skin cancer. Learning about medical care for skin cancer can help you take an active part in making choices about your care. This booklet tells about: ¿ Diagnosis and staging ¿ Treatment ¿ Follow-up care ¿ How to prevent another skin cancer from forming ¿ How to do a skin self-exam
Autorenporträt
TIP 63 Update--- To ensure that the content of this TIP is as up to date and as useful to readers as possible, SAMHSA, in January 2020, revised certain areas of all five parts. These changes will help provide readers with the latest information needed to understand medications for opioid use disorder. These changes included the following: . Updating statistics from SAMHSA, the Centers for Disease Control and Prevention, and other health authorities on opioid-related deaths, overdoses, accidents, and hospitalizations. . Updating the expanded list of other qualifying practitioners who are eligible to apply for a waiver to prescribe buprenorphine (i.e., clinical nurse specialists, certified registered nurse anesthetists, and certified nurse midwives). . Clarifying that buprenorphine is available in an extended-release injection formulation. . Adding information about the use of subdermal formulations of buprenorphine (i.e., Probuphine and Sublocade). . Adding information about possible clinical interactions between formulations of buprenorphine and naltrexone with various other medications and products. . Improving the language to make clear the importance of testing for HIV and hepatitis C. . Updating recommendations from the U.S. Preventive Services Task Force on performing drug screening for adults in primary care settings. . Removing or replacing broken hyperlinks to online resources.